Photo: Michael Barera | CC BY-SA 4.0 | Wikimedia Commons
Supreme Court Again Extends Temporary Order Preserving Mail And Telehealth Access To Mifepristone
Justice Samuel Alito extended a stay on Monday, May 11, 2026, preserving FDA rules that let mifepristone be prescribed by telehealth and shipped by mail.[1] The order keeps those rules in place through at least Thursday, May 14, 2026.[2]
The extension is temporary and the justices said it will run only for a few days while they consider whether to grant a longer stay of the 5th Circuit ruling.[1] If the 5th Circuit order took effect, its suspension of telehealth and mail dispensing would apply nationwide because FDA prescribing rules are federal.[3]
Louisiana filed the lawsuit in fall 2025 seeking to reinstate a pre-pandemic rule that required in-person dispensing and to block telemedicine and mail access.[2] A three-judge panel of the 5th U.S. Circuit Court of Appeals on May 1, 2026 ordered that mail access and telehealth prescribing be suspended while the case proceeds, and the panel was composed entirely of Republican appointees.[4]
Drugmakers Danco and GenBioPro say Louisiana lacks the proper legal standing and have asked the court to dismiss the suit.[4] Nearly two dozen Democratic-led states filed an amicus brief saying the 5th Circuit approach would let abortion-ban states override states that protect access, and former FDA leaders filed another brief defending the agency's science-based approvals.[3]
For now, the short extension preserves nationwide mail and telemedicine access to mifepristone while the Supreme Court weighs its next move, but the court could still allow the 5th Circuit order to take effect if it declines a longer stay.[1]
Show source details & analysis (5 sources)
📌 Key Facts
- On Monday, May 11, 2026, Justice Samuel Alito issued an administrative order extending a stay that preserves FDA rules allowing mifepristone to be prescribed via telehealth and shipped by mail through at least Thursday, May 14, 2026 (5 p.m. ET).
- The Supreme Court described the latest order as a short, temporary extension for a few more days beyond May 11, signaling the justices are still deliberating whether to grant a longer‑term stay of the 5th Circuit ruling.
- The underlying lawsuit was filed by Louisiana in fall 2025, challenging the FDA’s 2021 decision to drop the in‑person dispensing requirement and prompting a May 1, 2026 appeal ruling that would reinstate pre‑pandemic in‑person dispensing.
- A three‑judge 5th U.S. Circuit Court of Appeals panel — composed entirely of Republican appointees — ruled on May 1, 2026 that mail access and telehealth prescribing for mifepristone should be suspended while the case proceeds, but that order remains on hold because of the Supreme Court’s temporary stay.
- Drugmakers Danco and GenBioPro argue Louisiana’s asserted injuries to state sovereignty and finances are insufficient for standing and have asked the court to dismiss the suit on that basis.
- An amicus brief by nearly two dozen Democratic‑led states warns the 5th Circuit decision would elevate the policy choices of abortion‑banning states over states that protect access, and former FDA leaders filed a separate brief defending the agency’s science‑based process and warning the 5th Circuit’s approach would upend FDA’s drug‑approval system.
- The FDA first approved mifepristone in 2000, has repeatedly found it safe and effective, and medication abortion accounted for nearly two‑thirds of U.S. abortions in 2023.
- About one quarter of U.S. abortions now occur via telemedicine, and overall abortions have increased nationally since the 2022 Dobbs decision in part because of telehealth and mail access to abortion pills.
- The 5th Circuit panel relied in part on Louisiana’s claim that the state paid about $92,000 in 2025 Medicaid costs for emergency care for two women allegedly linked to out‑of‑state mifepristone use and said such costs would “almost certainly continue.”
📰 Source Timeline (5)
Follow how coverage of this story developed over time
May 11, 2026
9:14 PM
Abortion pill by mail allowed for at least 3 more days, the Supreme Court says
New information:
- On Monday, May 11, 2026, Justice Samuel Alito extended his prior administrative stay by three more days, keeping current telemedicine and mail‑dispensing rules for mifepristone in place through at least Thursday, May 14, 2026.
- The underlying dispute stems from a May 1, 2026 ruling by a three‑judge 5th U.S. Circuit Court of Appeals panel that would reinstate pre‑pandemic rules requiring in‑person dispensing of mifepristone in a clinic or doctor’s office.
- Louisiana filed the lawsuit in fall 2025 arguing that telemedicine and mail access to mifepristone undermine its state abortion ban and challenging FDA’s 2021 decision to drop the in‑person requirement as medically unnecessary.
- NPR notes that about one quarter of all U.S. abortions now occur via telemedicine, and that overall abortions have increased nationally since the Supreme Court’s 2022 Dobbs ruling in part because of telehealth and mail access to pills.
- The article reiterates that if the 5th Circuit ruling took effect without a Supreme Court stay, it would apply nationwide, including in states that protect abortion access, because FDA prescribing rules are national in scope.
- An amicus brief by nearly two dozen Democratic‑led states argues the 5th Circuit decision elevates the policy choices of states with abortion bans over states that have chosen to protect access to abortion care.
- Former FDA leaders from both parties filed an amicus brief defending the agency’s scientific process for approving mifepristone and later easing prescribing rules, warning the 5th Circuit’s approach would 'upend FDA's gold‑standard, science‑based drug approval system.'
8:11 PM
Supreme Court maintains abortion pill mifepristone access by mail for now
New information:
- On Monday, May 11, 2026, Justice Samuel Alito extended his administrative stay in the Danco and GenBioPro emergency appeals to 5 p.m. ET on Thursday, May 14, 2026, keeping mifepristone available by mail for at least three more days.
- The underlying May 1, 2026 order came from a three-judge 5th U.S. Circuit Court of Appeals panel composed entirely of Republican appointees, including two appointed by former President Donald Trump.
- Louisiana, leading the current challenge, is urging the Supreme Court to let the 5th Circuit order take effect while its lawsuit against remote dispensing proceeds, arguing the Biden administration is undermining the 2022 Dobbs ruling and that drugmakers seek higher profits and lower compliance costs.
- The 5th Circuit panel relied in part on Louisiana’s claim that it paid $92,000 in 2025 Medicaid costs for emergency care for two women who allegedly had complications from out-of-state mifepristone use, and said such costs would "almost certainly continue" because nearly 1,000 women a month have mifepristone-induced abortions in the state.
- The article notes that in the earlier, related litigation, the Supreme Court in 2023 preserved mifepristone access while the case proceeded and in 2024 unanimously found anti-abortion doctors lacked standing, with Justice Brett Kavanaugh writing that a desire to make a drug less available to others does not confer standing.
- Drugmakers Danco and GenBioPro argue in this new round that Louisiana’s asserted injuries to state sovereignty and finances are likewise insufficient for standing and that the suit should be dismissed on that basis.
8:03 PM
Supreme Court Continues Access to Abortion Pill by Mail, for a Few Days
New information:
- On Monday, May 11, 2026, the Supreme Court again extended Justice Samuel Alito's administrative stay that preserves current FDA rules allowing mifepristone prescriptions via telehealth and shipment by mail.
- The latest order continues the protections only for a few more days beyond the earlier May 11 deadline, signaling that the justices are still deliberating whether to grant a longer‑term stay of the 5th Circuit ruling.
- The article emphasizes that, during this short extension, the pre‑2023 in‑person dispensing requirements for mifepristone remain on hold nationwide while the Court decides its next step.
8:02 PM
Supreme Court temporarily extends access to a widely used abortion pill
New information:
- On Monday, May 11, 2026, Justice Samuel Alito issued a new administrative order keeping existing mifepristone access rules in place at least through Thursday, May 14, 2026.
- The underlying case now before the Supreme Court arises from a lawsuit filed by the state of Louisiana seeking to roll back FDA rules that allow mifepristone to be prescribed via telehealth and dispensed by mail or retail pharmacy.
- A three-judge panel of the 5th U.S. Circuit Court of Appeals had ruled that mail access and telehealth prescribing for mifepristone should be suspended while the case proceeds, but that ruling remains on hold because of the Supreme Court’s temporary order.
- The article reiterates that FDA first approved mifepristone in 2000 and has repeatedly determined it is safe and effective, and notes that medication abortion accounted for nearly two-thirds of U.S. abortions in 2023.
- The piece notes the Trump administration has not filed a merits brief in this dispute despite the challenge to federal regulations, reflecting an unusually limited public role in this specific Supreme Court clash so far.